# Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression

> **NCT00518479** · NA · COMPLETED · sponsor: **University of Leeds** · enrollment: 42 (actual)

## Conditions studied

- Hypertension
- Left Ventricular Hypertrophy

## Interventions

- **DRUG:** Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD
- **DRUG:** Valsartan 160mg OD; Moxonidine 400mcg OD

## Key facts

- **NCT ID:** NCT00518479
- **Lead sponsor:** University of Leeds
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** —
- **Final completion:** 2004-04
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2012-08-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00518479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00518479, "Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00518479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*